Presynaptic Imaging in Major Depressive Episodes After COVID-19
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in Canada
- Centre for Addiction and Mental HealthToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre for Addiction and Mental Health
- Trial code
- NCT06086366
- Record updated
- 11 February 2026
- Original description
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.Read full original descriptionShow less
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Inclusion: New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined; Age 18 to 75; Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Exclusion: Use of antidepressants in the previous month (6 weeks for fluoxetine); Use of stimulant medication affecting dopamine release in the previous month; Use of antipsychotics in the previous month; Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report; Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV); Positive urine drug or cotinine screen at any timepoint during the study; History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV); Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan); Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report; History of neurological disease (except migraine, and PASC) based on self-report; Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV); Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report; Severe allergic reaction to alcohol; Presence of cigarette smoking in the past two months, based on self-report; Breastfeeding (for females); Claustrophobia, based on self-report; Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns).